CG Oncology Past Earnings Performance
Past criteria checks 0/6
CG Oncology's earnings have been declining at an average annual rate of -49.3%, while the Biotechs industry saw earnings growing at 19.7% annually. Revenues have been growing at an average rate of 176.5% per year.
Key information
-49.3%
Earnings growth rate
62.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 176.5% |
| Return on equity | -10.0% |
| Net Margin | -13,419.1% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
CG Oncology: Promising Data, But Looks Expensive
Aug 26CG Oncology, Inc. (NASDAQ:CGON) Shares Could Be 42% Below Their Intrinsic Value Estimate
Jul 25
CG Oncology Bringing Undervalued Innovation To Bladder Cancer
Jul 09CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value
May 06Revenue & Expenses Breakdown
How CG Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1 | -72 | 14 | 0 |
| 31 Dec 23 | 0 | -68 | 10 | 0 |
| 30 Sep 23 | 0 | -58 | 9 | 0 |
| 31 Dec 22 | 0 | -44 | 6 | 0 |
| 31 Dec 21 | 10 | -18 | 5 | 0 |
Quality Earnings: CGON is currently unprofitable.
Growing Profit Margin: CGON is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CGON's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CGON's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CGON is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: CGON has a negative Return on Equity (-10%), as it is currently unprofitable.